Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 2004-2013

  Banwell, Claire M ^a   MacCartney, Donia P ^a   Guy, Michelle ^c   Miles, Alice E ^a   Uskokovic, Milan R ^b   Mansi, Janine ^c   Stewart, Paul M ^a   O'Neill, Laura P ^a   Turner, Bryan M ^a   Colston, Kay W ^c   Campbell, Moray J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b HOFFMANN LA ROCHE INC   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CALCITRIOL; CALCITRIOL DERIVATIVE; DNA METHYLTRANSFERASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; NUCLEAR RECEPTOR COREPRESSOR; NUCLEAR RECEPTOR COREPRESSOR 1; RO 262198; TRICHOSTATIN A; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DEACETYLATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

AZACITIDINE; BREAST NEOPLASMS; CALCITRIOL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLECALCIFEROL; FEMALE; HUMANS; HYDROXAMIC ACIDS; NUCLEAR PROTEINS; RECEPTORS, CALCITRIOL; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33646239624     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1218     Document Type: Article

References (61)

1. Lal A, Lash AE, Altschul SF, et al. A public database for gene expression in human cancers. Cancer Res 1999;59:5403-7.
2. Hayashi SI, Eguchi H, Tanimoto K, et al. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancer 2003;10:193-202.
3. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S. Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res 2003;63:958-64.
4. Shao Z, Yu L, Shen Z, Fontana JA. Retinoic acid nuclear receptor α (RARα) plays a major role in retinoid-mediated inhibition of growth in human breast carcinoma cells. Chin Med Sci J 1996;11:142-6.
5. Xu XC, Sneige N, Liu X, et al. Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis. Cancer Res 1997;57:4992-6.
6. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
7. Li J, Wang J, Wang J, et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J 2000;19:4342-50.
8. Fischle W, Dequiedt F, Hendzel MJ, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002;9:45-57.
9. Hermanson O, Glass CK, Rosenfeld MG. Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 2002;13:55-60.
10. Nagy L, Schwabe JW. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 2004;29:317-24.
11. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene 2000;246:9-21.
12. Zinser GM, Welsh J. Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol 2004.
13. Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst 1998; 90:461-3.
14. Fogelman Y, Rakover Y, Luboshitzky R. High prevalence of vitamin D deficiency among Ethiopian women immigrants to Israel: exacerbation during pregnancy and lactation. Isr J Med Sci 1995;31:221-4.
15. Schondorf T, Eisberg C, Wassmer G, et al. Association of the vitamin D receptor genotype with bone metastases in breast cancer patients. Oncology 2003;64:154-9.
16. Guy M, Lowe LC, Bretherton-Watt D, et al. Vitamin d receptor gene polymorphisms and breast cancer risk. Clin Cancer Res 2004;10:5472-81.
17. 3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 2000;19:5091-7.
18. Elstner E, Linker-Israeli M, Said J, et al. 20-epivitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995;55: 2822-30.
19. Miller CW, Morosetti R, Campbell MJ, Mendoza S, Koeffler HP. Integrity of the 1,25-dihydroxy vitamin D3 receptor in bone, lung, and other cancers. Mol Carcinog 1997;19:254-7.
20. Khanim FL, Gommersall LM, Wood VH, et al. Altered SMRT levels disrupt vitamin D(3) receptor signalling in prostate cancer cells. Oncogene 2004;23:6712-25.
21. Rashid SF, Moore JS, Walker E, et al. Synergistic growth inhibition of prostate cancer cells by 1α,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001;20:1860-72.
22. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H. Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000;6:512-8.
23. Vienonen A, Miettinen S, Manninen T, Altucci L, Wilhelm E, Ylikomi T. Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. Eur J Endocrinol 2003;148:469-79.
24. Zhang Z, Yamashita H, Toyama T, et al. NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Lett 2005. Epub 2005 Jul 11.
25. Girault I, Lerebours F, Amarir S, et al. Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003;9:1259-66.
26. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999-1006.
27. Uskokovic MR, Norman AW, Manchand PS, et al. Highly active analogs of 1α,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids 2001;66: 463-71.
28. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997;19:15-27.
29. Carlberg C. Ligand-mediated conformational changes of the VDR are required for gene transactivation. J Steroid Biochem Mol Biol 2004;89-90:227-32.
30. 3 and Gemini: purification, crystallization and preliminary X-ray diffraction analysis. J Steroid Biochem Mol Biol 2004;89-90:55-9.
31. Weyts FA, Dhawan P, Zhang X, et al. Novel Gemini analogs of 1α,25-dihydroxyvitamin D(3) with enhanced transcriptional activity. Biochem Pharmacol 2004;67:1327-36.
32. Paine TM, Soule HD, Pauley RJ, Dawson PJ. Characterization of epithelial phenotypes in mortal and immortal human breast cells. Int J Cancer 1992;50: 463-73.
33. Campbell MJ, Park S, Uskokovic MR, Dawson MI, Koeffler HP. Expression of retinoic acid receptor-β sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog. Endocrinology 1998; 139:1972-80.
34. Han SH, Jeon JH, Ju HR, et al. VDUP1 up-regulated by TGF-β1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 2003;22:4035-46.
35. Jeon JH, Lee KN, Hwang CY, Kwon KS, You KH, Choi I. Tumor suppressor VDUP1 increases p27kip1 stability by inhibiting JAB1. Cancer Res 2005;65: 4485-9.
36. Yang X, Young LH, Voigt JM. Expression of a vitamin D-regulated gene (VDUP-1) in untreated- and MNU-treated rat mammary tissue. Breast Cancer Res Treat 1998;48:33-44.
37. Akutsu N, Lin R, Bastien Y, et al. Regulation of gene Expression by 1α,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. Mol Endocrinol 2001;15: 1127-39.
38. 2-M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 2003; 278:48030-40.
39. Stathopoulos EN, Sanidas E, Kafousi M, et al. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005;16:240-6.
40. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
41. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
42. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61:1327-33.
43. Campbell MJ, Reddy GS, Koeffler HP. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 1997;66: 413-25.
44. Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ. Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003;133:2425-33S.
45. Metivier R, Penot G, Hubner MR, et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115:751-63.
46. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11: 695-707.
47. Vaisanen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C. Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha;,25-dihydroxyvitamin D(3). J Mol Biol 2005; 350:65-77.
48. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-6.
49. Vertino AM, Bula CM, Chen JR, et al. Nongenotropic, anti-apoptotic signaling of 1α,25(OH)2-vitamin D3 and analogs through the ligand binding domain (LBD) of the vitamin D receptor (VDR) in osteoblasts and osteocytes: mediation by Src, PI3, and JNK kinases. J Biol Chem 2005;280:14130-7.
50. Agadir A, Lazzaro G, Zheng Y, Zhang XK, Mehta R. Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis 1999;20: 577-82.
51. Banwell CM, O'Neill LP, Uskokovic MR, Campbell MJ. Targeting 1α,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J Steroid Biochem Mol Biol 2004;89-90:245-9.
52. Raval-Pandya M, Dhawan P, Barletta F, Christakos S. YY1 represses vitamin D receptor-mediated 25-hydroxyvitamin D(3)24-hydroxylase transcription: relief of repression by CREB-binding protein. Mol Endocrinol 2001;15:1035-46.
53. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995;17:423-30.
54. Ahmad KF, Melnick A, Lax S, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 2003;12:1551-64.
55. Jepsen K, Rosenfeld MG. Biological roles and mechanistic actions of co-repressor complexes. J Cell Sci 2002;115:689-98.
56. Jepsen K, Hermanson O, Onami TM, et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000;102: 753-63.
57. Hermanson O, Jepsen K, Rosenfeld MG. N-CoR controls differentiation of neural stem cells into astrocytes. Nature 2002;419:934-9.
58. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res 2001;61: 3858-62.
59. Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome-proliferator activated receptor-γ (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 2003;106:752-7.
60. Kollara A, Kahn HJ, Marks A, Brown TJ. Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat 2001;67:245-53.
61. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391:815-8.